Preventing heart damage from chemotherapy in older lymphoma patients
Official title: Prevention of Anthracycline Chemotherapy Cardiotoxicity
Funded at Beth Israel Deaconess Medical Center · NIH-11301152 · Data updated 2026-11-12
This study is looking to help older adults with lymphoma by finding ways to prevent heart damage from chemotherapy, figuring out who might be at risk, and understanding what patients and doctors prefer when it comes to treatment options.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 15, 2020 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $128,976 |
| NIH project number | 7K08HL146959-06 |
| Project ID | NIH-11301152 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults, specifically those aged 65 and above, who are diagnosed with lymphoma and may require anthracycline chemotherapy.
✕Less likely to help
Patients who are younger than 65 or those who do not have lymphoma may not benefit from this research.
What this research studies
This research focuses on preventing serious heart damage caused by anthracycline chemotherapy in older adults diagnosed with lymphoma. It aims to develop better prediction tools to identify patients at risk, analyze current methods of protecting the heart during treatment, and understand the preferences of patients and healthcare providers regarding treatment options. The research will utilize large databases and qualitative methods to gather comprehensive data over a five-year period. By addressing these critical areas, the project seeks to enhance the safety and effectiveness of chemotherapy for older patients.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of heart failure in older adults undergoing chemotherapy for lymphoma.
How similar studies have gone: Previous research has shown promising results in developing cardioprotective strategies for patients undergoing chemotherapy, indicating that this approach has potential for success.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Upshaw, Jenica — Beth Israel Deaconess Medical Center
- Study coordinator: Upshaw, Jenica
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
-
PPAR-alpha and sex differences in chemotherapy-related heart injury
This project looks at why doxorubicin causes different heart side effects in men and women, and tests heart-protective ideas to help patients who need this chemotherapy.
-
Preventing chemo-related heart damage in African American children
This project uses patients' own lab-grown heart cells to find genetic risks and ways to stop heart damage from the chemotherapy drug doxorubicin in African American children treated for cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.